Emergent BioSolutions to supply 44.75 million doses of BioThrax to U.S. Government over five years

Mon, 2011-10-03 10:11 AM

Emergent BioSolutions Inc. announced on Oct. 3 that it has received an award to supply the U.S. Government with 44.75 million doses of BioThrax (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion.

BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) for pre-exposure protection against anthrax infection.

To date, more than 10 million doses of BioThrax have been administered to more than 2.5 million individuals, says Emergent BioSolutions on its Website. “BioThrax is indicated for the active immunization of individuals between 18 and 65 years of age at high risk of exposure to anthrax,â€